for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Opiant Pharmaceuticals Inc

OPNT.OQ

Latest Trade

16.48USD

Change

0.48(+3.00%)

Volume

12,924

Today's Range

15.78

 - 

16.48

52 Week Range

10.00

 - 

23.32

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
16.00
Open
15.99
Volume
12,924
3M AVG Volume
0.43
Today's High
16.48
Today's Low
15.78
52 Week High
23.32
52 Week Low
10.00
Shares Out (MIL)
4.04
Market Cap (MIL)
64.66
Forward P/E
15.29
Dividend (Yield %)
--

Next Event

Opiant Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Opiant Pharmaceuticals Reports Q2 Earnings Per Share $0.31

Opiant Pharmaceuticals Expands Partnership With Sanofi

Opiant Pharmaceuticals Q1 Loss Per Share $0.44

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Opiant Pharmaceuticals Inc

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

Industry

Biotechnology & Drugs

Contact Info

201 Santa Monica Blvd Ste 500

+1.310.5985410

https://www.opiant.com/

Executive Leadership

Michael J. Sinclair

Executive Chairman of the Board

Roger Crystal

President, Chief Executive Officer, Director

David D O'Toole

Chief Financial Officer

Arvind M Agrawal

Executive Vice President - Medical Affairs

Phil Skolnick

Chief Scientific Officer

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-7.100

2019(E)

1.047
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.03
Price To Book (MRQ)
3.21
Price To Cash Flow (TTM)
40.84
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-69.55
Return on Equity (TTM)
-48.67

Latest News

Consort, Opiant to develop nasal spray for opioid overdose treatment

Britain's Consort Medical Plc said on Monday it had agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.

Consort and Opiant to work on nasal spray overdose treatment

Consort Medical Plc has agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc .

UPDATE 2-Emergent BioSolutions to buy Narcan maker Adapt Pharma

* Adapt partner Opiant soars in after-hours trading (Adds details and comment from conference call)

BRIEF-Opiant Pharma Reports Financial Results

* OPIANT PHARMACEUTICALS, INC. REPORTS FINANCIAL RESULTS FOR AUGUST 1, 2017, THROUGH DECEMBER 31, 2017, AND PROVIDES CORPORATE UPDATE Source text for Eikon: Further company coverage:

BRIEF-Opiant Pharma Says Teva Filed ANDA With FDA For Marketing Approval Of Generic Version Of Narcan 2 Mg/Spray

* OPIANT PHARMACEUTICALS SAYS ON FEB 27, CO AND ADAPT PHARMA OPERATIONS LIMITED RECEIVED NOTICE FROM TEVA PHARMACEUTICALS USA INC - SEC FILING

BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003

* OPIANT PHARMACEUTICALS INC - ANNOUNCES POSITIVE DATA FROM A PHASE I CLINICAL STUDY OF ITS PRODUCT CANDIDATE OPNT003

BRIEF-Opiant Pharmaceuticals To Record About $11.7 Million In Royalty

* OPIANT PHARMACEUTICALS TO RECORD APPROXIMATELY $11.7 MILLION IN ROYALTY AND MILESTONE PAYMENTS RELATED TO 2017 SALES OF NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE

BRIEF-Opiant Pharmaceuticals Receives About $5.3 Mln Of Cash From Exercise Of Outstanding Warrants

* OPIANT PHARMACEUTICALS RECEIVES APPROXIMATELY $5.3 MILLION OF CASH FROM EXERCISE OF OUTSTANDING WARRANTS Source text for Eikon: Further company coverage:

BRIEF-Opiant Pharma Reports Financial Developments Related To Narcan Nasal Spray For Opioid Overdose

* OPIANT PHARMACEUTICALS ANNOUNCES SIGNIFICANT FINANCIAL DEVELOPMENTS RELATED TO NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE

BRIEF-Opiant Pharmaceuticals, Inc. Reports Qtrly ‍net Loss Per Common Share $2.77​

* OPIANT PHARMACEUTICALS, INC. REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Opiant pharmaceuticals says ‍may offer & sell its shares through Cantor Fitzgerald

* Opiant Pharmaceuticals says may offer & sell through Cantor Fitzgerald its shares having aggregate offering price of up to $25 million - SEC filing Source text (http://bit.ly/2gQyRPi) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Opiant Pharmaceuticals files for mixed shelf of upto $150 mln

* Opiant Pharmaceuticals Inc files for mixed shelf of upto $150 million - sec filing Source text : http://bit.ly/2gmIQz2 Further company coverage:

BRIEF-Opiant Pharmaceuticals reports Q4 loss per share $0.17

* Opiant Pharmaceuticals Inc reports fiscal fourth quarter and full year 2017 financial results and provides corporate update

BRIEF-Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

* Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

BRIEF-Opiant Pharma, Titan Pharmac to explore new treatments for opioid abuse

* Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

BRIEF-Opiant Pharmaceuticals Inc provides an update on Narcan nasal spray

* Opiant Pharmaceuticals Inc provides an update on Narcan nasal spray

BRIEF-Opiant Pharmaceuticals says co and Torreya Partners entered into a supplemental engagement letter

* Opiant Pharmaceuticals Inc - on September 8, co and Torreya Partners entered into a supplemental engagement letter effective September 7

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up